Product news

Share this article:
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals announced that the FDA has approved a supplemental New Drug Application for Nexavar (sorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma, or liver cancer. Nexavar, an oral anticancer drug, is the first approved systemic therapy for liver cancer and the only one shown to significantly improve overall survival in patients with the disease.
 
Wyeth, announced that the FDA has approved Protonix (pantoprazole sodium) delayed-release oral suspension, providing adult patients who cannot swallow tablets with an effective and convenient way to treat their erosive gastroesophageal reflux disease.
 
AstraZeneca said the FDA has approved once-daily Seroquel XR (quetiapine fumarate) extended-release tablets for maintenance treatment of schizophrenia in adult patients.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.